| All patients | CAP | HCAP |
---|---|---|---|
n = 670 | n = 328 | n = 342 | |
Patient background | Â | Â | Â |
Age, median (IQR) | 77 (65–80) | 75 (59–83) | 80 (72–87) |
Male, n (%) | 430 (64.2) | 212 (64.6) | 218 (63.7) |
Comorbid conditions, n (%) | 635 (94.8) | 296 (90.2) | 339 (99.1) |
Previous antibiotics treatment, n (%) | 97 (14.5) | 34 (10.4) | 63 (18.4) |
Immunosuppressed, n (%) | 40 (6.0) | 19 (5.8) | 21 (6.1) |
Suspected aspiration, n (%) | 246 (36.7) | 50 (15.2) | 196 (57.3) |
Severity scores | Â | Â | Â |
  PSI score, median (IQR) | 110 (89–140) | 96 (73–120) | 125 (104–153) |
  PSI class, median (IQR) | 4 (3–5) | 4 (3–4) | 4 (4–5) |
Clinical outcomes | Â | Â | Â |
Initial treatment failure, n (%) | 78 (11.6) | 28 (8.5) | 50 (14.6) |
Antibiotics adverse effect, n (%) | 40 (6.0) | 19 (5.8) | 21 (6.1) |
ICU admission, n (%) | 81 (12.1) | 41 (12.5) | 40 (11.7) |
Length of antibiotic treatment, median (IQR) | 8 (6–11) | 7 (6–10) | 9 (7–13) |
Length of hospital stay, median (IQR) | 11 (8–19) | 9 (7–16) | 12 (9–22) |
In-hospital mortality, n (%) | 59 (8.8) | 19 (5.8) | 30 (8.8) |
Pathogen identified, n (%) | 417 (62.2) | 206 (62.8) | 211 (61.7) |
Streptococcus pneumoniae, n (%) | 139 (20.7) | 76 (23.2) | 63 (18.4) |
Haemophilus influenzae, n (%) | 122 (18.2) | 61 (18.6) | 61 (17.8) |
Moraxella catarrhalis, n (%) | 41 (6.1) | 20 (6.1) | 21 (6.1) |
Klebsiella pneumoniae, n (%) | 43 (6.4) | 11 (3.4) | 32 (9.4) |
Pseudomonas aeruginosa, n (%) | 29 (4.3) | 12 (3.7) | 17 (5.0) |
Staphylococcus aureus, n (%) | 11 (1.6) | 2 (0.6) | 9 (2.6) |
Mycoplasma pneumoniae, n (%) | 10 (1.5) | 9 (2.7) | 1 (0.3) |
Chlamydophila pneumoniae, n (%) | 8 (1.2) | 7 (1.0) | 1 (0.3) |
Legionella pneumophila, n (%) | 2 (0.3) | 0 | 2 (0.6) |